Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

This publication has 21 references indexed in Scilit:

• Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy
  Expert Opinion on Investigational Drugs, 2006
• Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer
  Journal of Urology, 2006
• Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
  Journal of Clinical Oncology, 2005
• Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer
  Journal of Clinical Oncology, 2005
• Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma
  Cancer, 2005
• Renal Failure with the Use of Zoledronic Acid
  New England Journal of Medicine, 2003
• Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer
  Journal of Urology, 2003
• Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
  New England Journal of Medicine, 2002
• BONE MINERAL DENSITY IN MEN TREATED WITH SYNTHETIC GONADOTROPIN-RELEASING HORMONE AGONISTS FOR PROSTATIC CARCINOMA
  Journal of Urology, 1999
• The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma
  Cancer, 1998